Mengis Capital Management Inc. bought a new position in shares of Agilent Technologies Inc (NYSE:A) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund bought 35,413 shares of the medical research company’s stock, valued at approximately $2,644,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Destination Wealth Management lifted its holdings in Agilent Technologies by 100.0% during the 1st quarter. Destination Wealth Management now owns 400 shares of the medical research company’s stock worth $32,000 after buying an additional 200 shares during the period. Financial Gravity Wealth Inc. acquired a new position in Agilent Technologies during the 1st quarter worth about $52,000. Knuff & Co LLC raised its position in shares of Agilent Technologies by 203.3% in the 1st quarter. Knuff & Co LLC now owns 910 shares of the medical research company’s stock worth $73,000 after acquiring an additional 610 shares in the last quarter. NEXT Financial Group Inc raised its position in shares of Agilent Technologies by 22.0% in the 2nd quarter. NEXT Financial Group Inc now owns 925 shares of the medical research company’s stock worth $69,000 after acquiring an additional 167 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its position in shares of Agilent Technologies by 36.3% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 1,193 shares of the medical research company’s stock worth $96,000 after acquiring an additional 318 shares in the last quarter.

A has been the subject of several research analyst reports. ValuEngine raised Valmont Industries from a “sell” rating to a “hold” rating in a research report on Friday, July 12th. Deutsche Bank lifted their price objective on Alphabet from $1,300.00 to $1,400.00 and gave the stock a “buy” rating in a research report on Wednesday, May 15th. Barclays set a $330.00 price objective on Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Monday, July 15th. Wolfe Research initiated coverage on Waters in a research report on Thursday, May 30th. They issued an “underperform” rating for the company. Finally, Piper Jaffray Companies set a $29.00 price objective on Bausch Health Companies and gave the stock a “buy” rating in a research report on Tuesday, June 11th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and ten have given a buy rating to the company’s stock. Agilent Technologies has a consensus rating of “Buy” and an average target price of $83.92.

Shares of Agilent Technologies stock opened at $70.37 on Tuesday. Agilent Technologies Inc has a one year low of $61.01 and a one year high of $82.27. The company has a market cap of $21.96 billion, a price-to-earnings ratio of 25.22, a price-to-earnings-growth ratio of 1.94 and a beta of 1.41. The company has a 50-day moving average price of $71.88. The company has a debt-to-equity ratio of 0.35, a current ratio of 3.41 and a quick ratio of 2.82.

Agilent Technologies (NYSE:A) last issued its earnings results on Tuesday, May 14th. The medical research company reported $0.71 EPS for the quarter, missing analysts’ consensus estimates of $0.72 by ($0.01). Agilent Technologies had a net margin of 22.25% and a return on equity of 19.71%. The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.27 billion. During the same period in the previous year, the firm earned $0.65 earnings per share. The business’s quarterly revenue was up 2.7% on a year-over-year basis. On average, sell-side analysts predict that Agilent Technologies Inc will post 3.05 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Wednesday, July 24th. Investors of record on Tuesday, July 2nd were given a $0.164 dividend. This represents a $0.66 dividend on an annualized basis and a yield of 0.93%. The ex-dividend date of this dividend was Monday, July 1st. Agilent Technologies’s payout ratio is 23.66%.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

See Also: Analyst Ratings Trading

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies Inc (NYSE:A).

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.